What pathologic response criteria do you use to determine the need for further adjuvant therapy in patients with breast cancer?

The question about which response criteria might guide further adjuvant therapy in HR+ disease after neo-adjuvant chemo is of unclear clinical significance currently. Until CDK4/6 inhibitors receive an FDA indication in the adjuvant setting, the only "systemic therapy" decision to be made after neo-...